Deepa Jeyakumar, MD

Articles by Deepa Jeyakumar, MD

The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia

ByDeepa Jeyakumar, MD,Susan M. O’Brien, MD

November 15th 2016

This article describes the clinical data that led to approval of these B-cell receptor inhibitors for the treatment of CLL, and highlights newer agents in clinical development that target the same kinases as the currently available therapies.

Latest Updated Articles

The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia
November 15th 2016

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)